Evidence map›Paper›PMID 36648018›Full record

ArticleRenal failure2023

Combination therapy with DHA and BMSCs suppressed podocyte injury and attenuated renal fibrosis by modulating the TGF-

Yongzhang Li, Suzhi Chen, Jinchuan Tan, Yan Zhou, Meifang Ren, Qian Zhang, Meijiao Zhao, Guodong Yuan, Wenxi Zhang, Fengwen Yang

Open access · goldAbstract read
In one paragraph

Article in Renal failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yongzhang LiDepartment of Urology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Suzhi ChenDepartment of Nephrology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Jinchuan TanDepartment of Nephrology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Yan ZhouDepartment of Urology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Meifang RenDepartment of Nephrology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Qian ZhangDepartment of Nephrology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Meijiao ZhaoDepartment of Nephrology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Guodong YuanDepartment of Nephrology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Wenxi ZhangDepartment of Pharmacy, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Fengwen YangDepartment of Nephrology, Hebei Province of Chinese Medicine, Shijiazhuang City, Hebei Province, China.
Hebei University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artemisinin has immunomodulatory, anti-inflammatory, and antifibrotic effects. Some studies have demonstrated that artemisinins have a protective effect on the kidney. DHA is a derivative of artemisinin and has effects similar to those of artemisinin. Human bone marrow-derived mesenchymal stem cells (BMSCs) accelerate renal repair following acute injury. In the study, we investigated the effects of combination therapy with DHA and BMSCs on membranous nephropathy (MN) mice. The 24-h urinary protein, serum total cholesterol (TC) and triglyceride (TG) levels, and renal histopathology, were measured to evaluate kidney damage. Anti-PLA2R, IgG, and complement 3 (C3) were detected by ELISA. The expression levels of the podocyte injury-related proteins were analyzed by immunohistochemistry. The protein expression levels of

Indexed as

Glomerulonephritis, MembranousKidney DiseasesPodocytesAnimalsArtemisininsFibrosisHumansImmunoglobulin GMiceSmad ProteinsTransforming Growth Factor beta1artemisininArtemisininsImmunoglobulin GSmad ProteinsTransforming Growth Factor beta1bone marrow mesenchymal stem cellsdihydroartemisininMembranous nephropathypodocyte injuryrenal fibrosisTGF-β1/Smad

Identifiers

PMID36648018
PMCPMC9848254
OpenAlexW4316927897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.